2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

B Besse; A Adjei; P Baas; P Meldgaard; M Nicolson; L Paz-Ares; M Reck; E F Smit; K Syrigos; R Stahel; E Felip; S Peters; Panel Members; ESMO

doi:10.1093/annonc/mdu123

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Ann Oncol. 2014 Aug;25(8):1475-84. doi: 10.1093/annonc/mdu123. Epub 2014 Mar 25.

Authors

B Besse¹, A Adjei², P Baas³, P Meldgaard⁴, M Nicolson⁵, L Paz-Ares⁶, M Reck⁷, E F Smit⁸, K Syrigos⁹, R Stahel¹⁰, E Felip¹¹, S Peters¹²; Panel Members; ESMO

Affiliations

¹ Thoracic Group, Department of Cancer Medicine, Gustave Roussy, Villejuif, France [email protected].
² Medicine Oncology, Roswell Park Cancer Institute, Buffalo, USA.
³ The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
⁴ Aarhus University Hospital, Aarhus, Denmark.
⁵ Aberdeen Royal Infirmary Anchor Unit, Aberdeen, UK.
⁶ Hospital Universitario Virgen del Rocio, Sevilla, Spain.
⁷ Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf, Germany.
⁸ Department of Pulmonary Diseases, Vrije University Medical Centre (VUMC), Amsterdam, The Netherlands.
⁹ Oncology Unit, Third Department of Medicine, Athens Chest Hospital Sotiria, Athens, Greece.
¹⁰ Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland.
¹¹ Medical Oncology, Vall D'Hebron University Hospital, Barcelona, Spain.
¹² Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

PMID: 24669016
DOI: 10.1093/annonc/mdu123

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.

Keywords: ESMO; consensus; first line; further lines; non-small-cell lung cancer; second line.

Publication types

Consensus Development Conference
Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Age Factors
Aged
Angiogenesis Inhibitors / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Carcinoma, Non-Small-Cell Lung / drug therapy*
Chemotherapy, Adjuvant* / methods
Chemotherapy, Adjuvant* / standards
Chemotherapy, Adjuvant* / statistics & numerical data
Cisplatin / administration & dosage
Combined Modality Therapy / methods
Combined Modality Therapy / standards
Combined Modality Therapy / statistics & numerical data
Consensus
Drug Substitution / methods
Drug Substitution / standards
Humans
Lung Neoplasms / drug therapy*
Maintenance Chemotherapy / standards
Maintenance Chemotherapy / statistics & numerical data
Neoadjuvant Therapy* / methods
Neoadjuvant Therapy* / standards
Neoadjuvant Therapy* / statistics & numerical data

Substances

Angiogenesis Inhibitors
Carboplatin
Cisplatin